• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
GLYC

GLYC

GlycoMimetics, Inc.

NASDAQHealthcareBiotechnologyUS

USD15.71

-0.45 (-2.76%)

Company Profile

CEO

Stephanie R. Irish CPA

IPO Date

2014-01-10

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$16.25

Prev. Close

$16.15

Day Low

$15.52

Day High

$17.39

52W Low

$0.15

52W High

$63.00

Market Cap

$1.01B

Volume

0.00M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

21.1%

Avg Negative

3.3%

Avg Neutral

75.8%

News Feed

GlycoMimetics to Present at Jefferies 2021 Virtual Healthcare Conference

Business Wire·5/27/2021·↑ positive

Implied Volatility Surging for GlycoMimetics (GLYC) Stock Options

Zacks Investment Research·5/20/2021·↑ positive

GlycoMimetics A Buy On Potential 2022 AML Data

Seeking Alpha·5/19/2021·↑ positive

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/3/2021·↓ negative

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021

Business Wire·5/3/2021·↑ positive

GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model

Business Wire·4/10/2021·↑ positive

GlycoMimetics to Share GMI-1359 and Galectin-3 Antagonist Program Data at AACR 2021 Meeting

Business Wire·3/10/2021·↑ positive

GlycoMimetics, Inc.'s (GLYC) CEO Rachel King on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha·3/2/2021·↓ negative

GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences

Business Wire·2/26/2021·↑ positive

GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2

Business Wire·2/23/2021·↑ positive